Zhenggang Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhenggang Guo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Ye Wang
8 shared publicationsQianqian Guo
7 shared publicationsLin Zhao
Department of Anaesthesiology, Peking University Shougang Hospital, Beijing, China
6 shared publicationsMeng Wu
6 shared publicationsQi An
Department of Anaesthesiology, Peking University Shougang Hospital, Beijing, China
6 shared publicationsChunling Fan
4 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-10
Hydromorphone is Noninferior to Dexamethasone as an Adjuvant to Ropivacaine for Transversus Abdominis Plane Block After Laparoscopic Colorectal Cancer Surgery: A Randomized, Double-Blind Trial
Purpose: The transversus abdominis plane (TAP) block provides analgesia for laparoscopic colorectal cancer surgery. To extend block duration and provide adequate analgesia, adjuvants such as dexamethasone and hydromorphone have been used. This study hypothesized that hydromorphone is an effective adjuvant for local anesthetics, and it is noninferior to dexamethasone for the TAP block duration. Patients and Methods: Eighty-one subjects undergoing laparoscopic colorectal cancer surgery were randomized to Group C (given TAP- block with 40 mL of 0.25% ropivacaine and saline), Group H (given TAP- block with 40 mL of 0.25% ropivacaine, 0.05mg/mL hydromorphone and saline), or Group D (given TAP- block with 40 mL of 0.25% ropivacaine, 0.25mg/mL dexamethasone and saline). The primary outcome was the first request time for patient-controlled intravenous analgesia (PCIA). Additional outcomes included visual analog scale (VAS) scores, total opioid use, side effects including nausea, vomiting, pruritus, and respiratory depression. Results: Eighty subjects completed the study. Compared with Group C (428.6 ± 175.3 min), both Group D (546.1 ± 190.5 min; P = 0.032) and Group H (620.2 ± 185.3 min; P = 0.001) showed significantly prolonged first request time for PCIA. Moreover, the difference between the mean first request time for PCIA in Group H and Group D was 74.0 (95% confidence interval [CI], − 37.7 to 185.7, P = 0.020 for noninferiority). The VAS score on coughing in Group D showed a significant decrease compared with Group C at 12 h post-operatively (P = 0.006). No significant differences were observed in other outcomes. Conclusion: The addition of hydromorphone to ropivacaine in TAP block provided noninferior analgesia duration compared to dexamethasone for laparoscopic colorectal cancer surgery.
- 1 March 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-10
Open AccessHydromorphone is Noninferior to Dexamethasone as an Adjuvant to Ropivacaine for Transversus Abdominis Plane Block After Laparoscopic Colorectal Cancer Surgery: A Randomized, Double-Blind Trial
Purpose: The transversus abdominis plane (TAP) block provides analgesia for laparoscopic colorectal cancer surgery. To extend block duration and provide adequate analgesia, adjuvants such as dexamethasone and hydromorphone have been used. This study hypothesized that hydromorphone is an effective adjuvant for local anesthetics, and it is noninferior to dexamethasone for the TAP block duration. Patients and Methods: Eighty-one subjects undergoing laparoscopic colorectal cancer surgery were randomized to Group C (given TAP- block with 40 mL of 0.25% ropivacaine and saline), Group H (given TAP- block with 40 mL of 0.25% ropivacaine, 0.05mg/mL hydromorphone and saline), or Group D (given TAP- block with 40 mL of 0.25% ropivacaine, 0.25mg/mL dexamethasone and saline). The primary outcome was the first request time for patient-controlled intravenous analgesia (PCIA). Additional outcomes included visual analog scale (VAS) scores, total opioid use, side effects including nausea, vomiting, pruritus, and respiratory depression. Results: Eighty subjects completed the study. Compared with Group C (428.6 ± 175.3 min), both Group D (546.1 ± 190.5 min; P = 0.032) and Group H (620.2 ± 185.3 min; P = 0.001) showed significantly prolonged first request time for PCIA. Moreover, the difference between the mean first request time for PCIA in Group H and Group D was 74.0 (95% confidence interval [CI], − 37.7 to 185.7, P = 0.020 for noninferiority). The VAS score on coughing in Group D showed a significant decrease compared with Group C at 12 h post-operatively (P = 0.006). No significant differences were observed in other outcomes. Conclusion: The addition of hydromorphone to ropivacaine in TAP block provided noninferior analgesia duration compared to dexamethasone for laparoscopic colorectal cancer surgery.
- Open Access
- 19 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (16) , e37841
Successful treatment of gastric cancer 10 years after heart transplantation: A case report
Background: While survival rates among cardiac allograft recipients have improved, there has been a rise in post-transplant malignancies, with gastric cancer being less commonly reported. This study presented a successful treatment of gastric cancer in an individual 10 years after undergoing a heart transplant. Case presentation: A 66-year-old Chinese man presented to the gastrointestinal clinic with a complaint of diagnosis of gastric cancer for 4 months and treated with neoadjuvant therapy for 1 month. He has undergone orthotopic heart transplantation 10 years earlier due to a myocardial infarction. Physical examination and laboratory tests did not reveal any significant abnormalities. Abdominal contrast-enhanced computed tomography (CT) imaging indicated a gastric mass near the greater curvature, with gastroscopy suggesting a carcinoma at the esophagogastric junction, Siewert III. An echocardiogram indicated left atrial enlargement with mild mitral and tricuspid regurgitation. The diagnosis suggested that his gastric cancer at the esophagogastric junction was a consequence of long-term immunosuppressive therapy. A multidisciplinary team (MDT) consultation recommended a proximal radical gastrectomy. Postoperatively, the patient received 4 cycles of adjuvant chemotherapy with XELOX combined with Herceptin, initiated a month after surgery. During the 1-year follow-up, the patient showed commendable recovery, with no signs of tumor recurrence or metastasis. Conclusion: This case underscores the potential risk of malignancy from immunosuppressive agents in transplant recipients. The successful management of this complex scenario underscores the indispensable role of an MDT approach in treating such unique and challenging cases.
- 19 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (16) , e37841
Open AccessSuccessful treatment of gastric cancer 10 years after heart transplantation: A case report
Background: While survival rates among cardiac allograft recipients have improved, there has been a rise in post-transplant malignancies, with gastric cancer being less commonly reported. This study presented a successful treatment of gastric cancer in an individual 10 years after undergoing a heart transplant. Case presentation: A 66-year-old Chinese man presented to the gastrointestinal clinic with a complaint of diagnosis of gastric cancer for 4 months and treated with neoadjuvant therapy for 1 month. He has undergone orthotopic heart transplantation 10 years earlier due to a myocardial infarction. Physical examination and laboratory tests did not reveal any significant abnormalities. Abdominal contrast-enhanced computed tomography (CT) imaging indicated a gastric mass near the greater curvature, with gastroscopy suggesting a carcinoma at the esophagogastric junction, Siewert III. An echocardiogram indicated left atrial enlargement with mild mitral and tricuspid regurgitation. The diagnosis suggested that his gastric cancer at the esophagogastric junction was a consequence of long-term immunosuppressive therapy. A multidisciplinary team (MDT) consultation recommended a proximal radical gastrectomy. Postoperatively, the patient received 4 cycles of adjuvant chemotherapy with XELOX combined with Herceptin, initiated a month after surgery. During the 1-year follow-up, the patient showed commendable recovery, with no signs of tumor recurrence or metastasis. Conclusion: This case underscores the potential risk of malignancy from immunosuppressive agents in transplant recipients. The successful management of this complex scenario underscores the indispensable role of an MDT approach in treating such unique and challenging cases.
- Open Access
- 2 January 2024
- Published by Springer Nature in BMC Surgery
- Vol. 24 (1) , 1-9
Different doses of nalmefene combined with hydromorphone hydrochloride for postoperative analgesia after colorectal surgery: a randomized controlled study
Hydromorphone hydrochloride has a satisfactory postoperative analgesic effect for patients with colorectal cancer but is accompanied by a relatively high incidence of adverse events. Low-doses of naloxone combined with opioids for patient-controlled analgesia can reduce the incidence of drug-related adverse events. Nalmefene is a more selective opioid receptor antagonist than naloxone. The aim of this study was to determine the impact of low-doses of nalmefene on the analgesic effect and incidence of adverse events of patients with hydromorphone patient-controlled analgesia (PCA) undergoing colorectal radical surgery. Ninety-nine patients undergoing elective laparoscopic or hand-assisted laparoscopic radical surgery under general anaesthesia were randomly divided into three groups. Group N1 received hydromorphone hydrochloride 0.15 mg/kg + nalmefene 2 µg/kg; Group N2 received hydromorphone hydrochloride 0.15 mg/kg + nalmefene 0.5 µg/kg; and the control group (Group C) received hydromorphone hydrochloride 0.15 mg/kg. All medications were diluted to 100 ml with normal saline. The primary outcome was pain intensity at 12 h after surgery; the secondary outcomes were the occurrence of nausea, vomiting and pruritus and the total analgesic consumption of the PCA pump at 1 h, 6 h, 12 h, 24 and 48 h after surgery. The NRS scores of Group N1 (2 µg/kg) were significantly lower than those of Group C (P = 0.025), and no difference was found between group N2 and group C (P > 0.05). Among the three groups, the NRS scores of Group N1 (2 µg/kg) were significantly lower than those of Group C at 12 h (P = 0.01) and 48 h (P = 0.01) postoperatively. Compared with 12 h postoperatively, the NRS scores were lower at 24 h postoperatively in Group N1 and Group C (P < 0.05) and significantly lower at 48 h postoperatively in all three groups (P < 0.001). There was a significant difference in the incidence of pruritus among the three groups (P = 0.036). Nalmefene at a dosage of 2 µg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. The trial was registered with the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- 2 January 2024
- Published by Springer Nature in BMC Surgery
- Vol. 24 (1) , 1-9
Open AccessDifferent doses of nalmefene combined with hydromorphone hydrochloride for postoperative analgesia after colorectal surgery: a randomized controlled study
Hydromorphone hydrochloride has a satisfactory postoperative analgesic effect for patients with colorectal cancer but is accompanied by a relatively high incidence of adverse events. Low-doses of naloxone combined with opioids for patient-controlled analgesia can reduce the incidence of drug-related adverse events. Nalmefene is a more selective opioid receptor antagonist than naloxone. The aim of this study was to determine the impact of low-doses of nalmefene on the analgesic effect and incidence of adverse events of patients with hydromorphone patient-controlled analgesia (PCA) undergoing colorectal radical surgery. Ninety-nine patients undergoing elective laparoscopic or hand-assisted laparoscopic radical surgery under general anaesthesia were randomly divided into three groups. Group N1 received hydromorphone hydrochloride 0.15 mg/kg + nalmefene 2 µg/kg; Group N2 received hydromorphone hydrochloride 0.15 mg/kg + nalmefene 0.5 µg/kg; and the control group (Group C) received hydromorphone hydrochloride 0.15 mg/kg. All medications were diluted to 100 ml with normal saline. The primary outcome was pain intensity at 12 h after surgery; the secondary outcomes were the occurrence of nausea, vomiting and pruritus and the total analgesic consumption of the PCA pump at 1 h, 6 h, 12 h, 24 and 48 h after surgery. The NRS scores of Group N1 (2 µg/kg) were significantly lower than those of Group C (P = 0.025), and no difference was found between group N2 and group C (P > 0.05). Among the three groups, the NRS scores of Group N1 (2 µg/kg) were significantly lower than those of Group C at 12 h (P = 0.01) and 48 h (P = 0.01) postoperatively. Compared with 12 h postoperatively, the NRS scores were lower at 24 h postoperatively in Group N1 and Group C (P < 0.05) and significantly lower at 48 h postoperatively in all three groups (P < 0.001). There was a significant difference in the incidence of pruritus among the three groups (P = 0.036). Nalmefene at a dosage of 2 µg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. The trial was registered with the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- Open Access
- 30 August 2023
- Published by Springer Nature in Research Square
Different-doses Nalmefene Combined with Hydromorphone Hydrochloride for Postoperative Analgesia After Colorectal Surgery: A Randomized Controlled Study
Background Hydromorphone hydrochloride has a satisfactory postoperative analgesic effect for patients with colorectal cancer but isaccompanied by a relatively high incidence of adverse events. Low-dose naloxone combined with opioids for patient-controlled analgesia (PCA) can reduce the incidence of drug-related adverse events. Nalmefene is a more selective opioid receptor antagonist than naloxone. We hypothesized that low-dose nalmefene combined with hydromorphone hydrochloride for PCA could enhance the analgesic effect and reduce the incidence of adverse events of hydromorphone hydrochloride. Methods The research was designed as a randomized, double-blind, controlled study. Ninety-nine patients undergoing selective radical resection of colorectal cancer were enrolled and randomly divided into three groups. The postoperative analgesia plan was hydromorphone hydrochloride (0.15 mg/kg) added to 100 ml of normal saline for all groups, to which 2 μg/kg nalmefene was added in Group N1 and 0.5 μg/kg nalmefene was added in Group N2, Group C received hydromorphone hydrochloride only. The PCA was connected to the patient after the operation. The following data were recorded: the degree of pain (NRS score) at 1, 6, 12, 24 and 48 h after surgery; the occurrence of nausea, vomiting and pruritus; the total analgesic consumption of the PCA pump; the time to postoperative exhaust; the time to drainage tube extubation; and the overall length of hospital stay. Results The NRS scores of Group N1 (2 μg/kg) were significantly lower than those of Group C (P = 0.25). Among the three groups, the NRS scores of Group N1 (2 μg/kg) were significantly lower than those of Group C at 12 h (P = 0.01) and 48 h (P = 0.01) post-operatively. Compared with 12 hours post-operatively, the NRS scores were lower at 24 hours post-operatively in Group N1 and Group C (P < 0.05), and significantly lower at 48 hours post-operatively in all three groups (P < 0.001). There was a significant difference in the incidence of pruritus among the three groups (P = 0.036). Conclusions Nalmefene at a dosage of 2 μg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. Trial Registration: The trial was registered with the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- 30 August 2023
- Published by Springer Nature in Research Square
Open AccessDifferent-doses Nalmefene Combined with Hydromorphone Hydrochloride for Postoperative Analgesia After Colorectal Surgery: A Randomized Controlled Study
Background Hydromorphone hydrochloride has a satisfactory postoperative analgesic effect for patients with colorectal cancer but isaccompanied by a relatively high incidence of adverse events. Low-dose naloxone combined with opioids for patient-controlled analgesia (PCA) can reduce the incidence of drug-related adverse events. Nalmefene is a more selective opioid receptor antagonist than naloxone. We hypothesized that low-dose nalmefene combined with hydromorphone hydrochloride for PCA could enhance the analgesic effect and reduce the incidence of adverse events of hydromorphone hydrochloride. Methods The research was designed as a randomized, double-blind, controlled study. Ninety-nine patients undergoing selective radical resection of colorectal cancer were enrolled and randomly divided into three groups. The postoperative analgesia plan was hydromorphone hydrochloride (0.15 mg/kg) added to 100 ml of normal saline for all groups, to which 2 μg/kg nalmefene was added in Group N1 and 0.5 μg/kg nalmefene was added in Group N2, Group C received hydromorphone hydrochloride only. The PCA was connected to the patient after the operation. The following data were recorded: the degree of pain (NRS score) at 1, 6, 12, 24 and 48 h after surgery; the occurrence of nausea, vomiting and pruritus; the total analgesic consumption of the PCA pump; the time to postoperative exhaust; the time to drainage tube extubation; and the overall length of hospital stay. Results The NRS scores of Group N1 (2 μg/kg) were significantly lower than those of Group C (P = 0.25). Among the three groups, the NRS scores of Group N1 (2 μg/kg) were significantly lower than those of Group C at 12 h (P = 0.01) and 48 h (P = 0.01) post-operatively. Compared with 12 hours post-operatively, the NRS scores were lower at 24 hours post-operatively in Group N1 and Group C (P < 0.05), and significantly lower at 48 hours post-operatively in all three groups (P < 0.001). There was a significant difference in the incidence of pruritus among the three groups (P = 0.036). Conclusions Nalmefene at a dosage of 2 μg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. Trial Registration: The trial was registered with the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- 1 May 2023
- Vol. 26 (3) , 375-382
Intrathecal Analgesia via a Percutaneous Port With Patient-Controlled Intrathecal Analgesia for the Management of Movement-Evoked Breakthrough Cancer Pain of Refractory Lower Extremity Cancer Pain: A Retrospective Review
Background: Intrathecal analgesia (ITA) is a valuable treatment option for refractory cancer related pain. However, there is still no general consensus on the analgesic effect of movement evoked breakthrough pain (MEBTP) in the ITA setting.Objectives: This study aimed to conduct a retrospective observational study to examine the effect of ITA via percutaneous port (ITAPP) with patient-controlled ITA (PCIA) on analgesic efficacy, emphasizing MEBTP in patients with refractory lower extremity cancer pain.Study Design: A retrospective chart review included all patients with refractory lower extremity cancer pain who received ITAPP at our hospital between January 2017 and December 2020.Methods: Data on the Numeric Rating Scale scores of spontaneous resting pain intensity (SRPI) and MEBTP intensity (MEPI), opioid doses, and perceived time to onset were collected from medical records prior to ITAPP and at a one-month postimplant visit.Results: A total of 16 patients were included in the study group. Mean SRPI decreased from 8.75 pre-ITAPP to 3.75 post-ITAPP (P < 0.05); mean MEPI fell from 8.83 pre-ITAPP to 4.25 post-ITAPP (P < 0.05); mean daily morphine equivalent dosing decreased from 360 mg/d to 48 mg/d (P < 0.05); and mean daily morphine equivalent dosing for MEBTP decreased from 87 mg/d to 6 mg/d (P < 0.05). Both total and breakthrough dosing of conventional opioid medications significantly decreased following the initiation of ITAPP with PCIA. The mean perceived time to onset with conventional MEBT medications was 38 minutes, and the mean perceived time to onset with PCIA was 8 minutes (P < 0.05).Limitations: An effective analysis of IT opioid efficacy was not possible because the power of such a small sample size was low. Second, it is a retrospective study without long-term follow-ups.Conclusions: In patients with refractory lower extremity cancer pain, ITAPP with PCIA was associated with improved pain control. Compared with conventional MEBTP regimens, appropriate ITAPP with PCIA provided superior analgesia and a much faster onset of action.
- 1 May 2023
- Vol. 26 (3) , 375-382
Intrathecal Analgesia via a Percutaneous Port With Patient-Controlled Intrathecal Analgesia for the Management of Movement-Evoked Breakthrough Cancer Pain of Refractory Lower Extremity Cancer Pain: A Retrospective Review
Background: Intrathecal analgesia (ITA) is a valuable treatment option for refractory cancer related pain. However, there is still no general consensus on the analgesic effect of movement evoked breakthrough pain (MEBTP) in the ITA setting.Objectives: This study aimed to conduct a retrospective observational study to examine the effect of ITA via percutaneous port (ITAPP) with patient-controlled ITA (PCIA) on analgesic efficacy, emphasizing MEBTP in patients with refractory lower extremity cancer pain.Study Design: A retrospective chart review included all patients with refractory lower extremity cancer pain who received ITAPP at our hospital between January 2017 and December 2020.Methods: Data on the Numeric Rating Scale scores of spontaneous resting pain intensity (SRPI) and MEBTP intensity (MEPI), opioid doses, and perceived time to onset were collected from medical records prior to ITAPP and at a one-month postimplant visit.Results: A total of 16 patients were included in the study group. Mean SRPI decreased from 8.75 pre-ITAPP to 3.75 post-ITAPP (P < 0.05); mean MEPI fell from 8.83 pre-ITAPP to 4.25 post-ITAPP (P < 0.05); mean daily morphine equivalent dosing decreased from 360 mg/d to 48 mg/d (P < 0.05); and mean daily morphine equivalent dosing for MEBTP decreased from 87 mg/d to 6 mg/d (P < 0.05). Both total and breakthrough dosing of conventional opioid medications significantly decreased following the initiation of ITAPP with PCIA. The mean perceived time to onset with conventional MEBT medications was 38 minutes, and the mean perceived time to onset with PCIA was 8 minutes (P < 0.05).Limitations: An effective analysis of IT opioid efficacy was not possible because the power of such a small sample size was low. Second, it is a retrospective study without long-term follow-ups.Conclusions: In patients with refractory lower extremity cancer pain, ITAPP with PCIA was associated with improved pain control. Compared with conventional MEBTP regimens, appropriate ITAPP with PCIA provided superior analgesia and a much faster onset of action.
- Open Access
- 17 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1607
Safety and Efficacy of Dexmedetomidine for Bronchoscopy: A Systematic Review and Meta-Analysis
(1) Background: Anesthetic sedatives are widely used for bronchoscopy, and controversy surrounds the safety and efficacy of dexmedetomidine compared to other sedatives. The aim of this study is to evaluate the safety and efficacy of dexmedetomidine in bronchoscopy through a systematic review. (2) Methods: PubMed, Embase, Google Scholar, and Cochrane Library electronic databases were searched for a randomized controlled study of dexmedetomidine (Group D) or other sedative drugs (Group C) for bronchoscopy. Data extraction, quality assessment, and risk of bias analysis were performed in accordance with the preferred reporting items for systematic review and meta-analysis requirements. Meta-analysis was performed using RevMan 5.2. (3) Results: Nine studies were included, with a total of 765 cases. Compared to Group C, the incidence of hypoxemia (OR = 0.40, 95% CI (0.25, 0.64) p = 0.0001, I2 = 8%) and tachycardia (OR = 0.44, 95% CI (0.26,0.74), p = 0.002, I2 = 14%) were lower, but bradycardia (OR = 3.71, 95% CI (1.84, 7.47), p = 0.0002, I2 = 0%) was higher in Group D; no significant difference was observed in other outcome indicators. (4) Conclusions: Dexmedetomidine reduces the incidence of hypoxemia and tachycardia during bronchoscopy but is more likely to provoke bradycardia.
- 17 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1607
Open AccessSafety and Efficacy of Dexmedetomidine for Bronchoscopy: A Systematic Review and Meta-Analysis
(1) Background: Anesthetic sedatives are widely used for bronchoscopy, and controversy surrounds the safety and efficacy of dexmedetomidine compared to other sedatives. The aim of this study is to evaluate the safety and efficacy of dexmedetomidine in bronchoscopy through a systematic review. (2) Methods: PubMed, Embase, Google Scholar, and Cochrane Library electronic databases were searched for a randomized controlled study of dexmedetomidine (Group D) or other sedative drugs (Group C) for bronchoscopy. Data extraction, quality assessment, and risk of bias analysis were performed in accordance with the preferred reporting items for systematic review and meta-analysis requirements. Meta-analysis was performed using RevMan 5.2. (3) Results: Nine studies were included, with a total of 765 cases. Compared to Group C, the incidence of hypoxemia (OR = 0.40, 95% CI (0.25, 0.64) p = 0.0001, I2 = 8%) and tachycardia (OR = 0.44, 95% CI (0.26,0.74), p = 0.002, I2 = 14%) were lower, but bradycardia (OR = 3.71, 95% CI (1.84, 7.47), p = 0.0002, I2 = 0%) was higher in Group D; no significant difference was observed in other outcome indicators. (4) Conclusions: Dexmedetomidine reduces the incidence of hypoxemia and tachycardia during bronchoscopy but is more likely to provoke bradycardia.
- Open Access
- 8 November 2022
- Published by Springer Nature in Research Square
Enhanced Postoperative Analgesic Effect of Hydromorphone Hydrochloride and Decreased Incidence of Pruritus via Continuous Low-dose Pumping of Nalmefene: A Randomized Controlled Study
Background: Hydromorphone hydrochloride has a satisfactory effect on postoperative analgesia for patients with colorectal cancer, yet accompanied by a relatively incidence of adverse events. Low-dose naloxone combined with opioids for Patient Controlled Analgesia (PCA) can reduce the incidence of drug-related adverse events. Meanwhile, Nalmefene is a more selective opioid receptor antagonist than naloxone. This study hypothesized that low-dose nalmefene combined with hydromorphone hydrochloride for PCA could enhance the analgesic effect of the drug and reduce the incidence of adverse events. Methods The present research was designed as a randomized, double-blind, controlled study. Ninety-nine patients undergoing selective radical resection of colorectal cancer were enrolled and randomly divided into three groups. The postoperative analgesia plan of the three groups was Hydromorphone hydrochloride (0.15mg/kg) added to 100 ml of normal saline, among which 2μg/kg of Nalmefene was added to group N1, 0.5μg/kg Nalmefene to group N2, and normal saline only in group C. The induction and maintenance plan of general anesthesia were the same in the three groups, and PCA was connected after operation. Furthermore, the following data were recorded, including the degree of pain (NRS score) at 1, 6, 12, 24 and 48h after surgery, the occurrence of nausea, vomiting and pruritus, the frequency of PCA, the time of postoperative exhaust, the time of drainage tube extubation, and the overall length of hospital stay. Results After being approved by the Ethics Committee of our hospital, our study included ninety-three patients with written informed consent provided. Compared with group C, the NRS scores were significantly lower in group N1 at 12 and 48 hours after operation (PConclusionNalmefene at the dosage of 2μg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. Trial Registration: The trial was registered on the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- 8 November 2022
- Published by Springer Nature in Research Square
Open AccessEnhanced Postoperative Analgesic Effect of Hydromorphone Hydrochloride and Decreased Incidence of Pruritus via Continuous Low-dose Pumping of Nalmefene: A Randomized Controlled Study
Background: Hydromorphone hydrochloride has a satisfactory effect on postoperative analgesia for patients with colorectal cancer, yet accompanied by a relatively incidence of adverse events. Low-dose naloxone combined with opioids for Patient Controlled Analgesia (PCA) can reduce the incidence of drug-related adverse events. Meanwhile, Nalmefene is a more selective opioid receptor antagonist than naloxone. This study hypothesized that low-dose nalmefene combined with hydromorphone hydrochloride for PCA could enhance the analgesic effect of the drug and reduce the incidence of adverse events. Methods The present research was designed as a randomized, double-blind, controlled study. Ninety-nine patients undergoing selective radical resection of colorectal cancer were enrolled and randomly divided into three groups. The postoperative analgesia plan of the three groups was Hydromorphone hydrochloride (0.15mg/kg) added to 100 ml of normal saline, among which 2μg/kg of Nalmefene was added to group N1, 0.5μg/kg Nalmefene to group N2, and normal saline only in group C. The induction and maintenance plan of general anesthesia were the same in the three groups, and PCA was connected after operation. Furthermore, the following data were recorded, including the degree of pain (NRS score) at 1, 6, 12, 24 and 48h after surgery, the occurrence of nausea, vomiting and pruritus, the frequency of PCA, the time of postoperative exhaust, the time of drainage tube extubation, and the overall length of hospital stay. Results After being approved by the Ethics Committee of our hospital, our study included ninety-three patients with written informed consent provided. Compared with group C, the NRS scores were significantly lower in group N1 at 12 and 48 hours after operation (PConclusionNalmefene at the dosage of 2μg/kg enhances the postoperative analgesic effect of hydromorphone hydrochloride and reduces the occurrence of postoperative pruritus. Trial Registration: The trial was registered on the Chinese Clinical Trial Registry (Registration number: ChiCTR2000033520, date: 03/06/2020).
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 81 (11) , 931-942
Ketamine Regulates the Autophagy Flux and Polarization of Microglia through the HMGB1-RAGE Axis and Exerts Antidepressant Effects in Mice
Depression is a leading cause of disability worldwide. Here, we explored the role of the HMGB1-RAGE pathway in lipopolysaccharide (LPS)-induced depression-like behavior and microglial autophagy flux, neuroinflammation, and polarization in a mouse model. Male C57BL/6 mice were infused with LPS in the abdominal cavity to induce a depression model. They then underwent testing to assess behavior and cognition. Real-time fluorescent quantitative polymerase chain reaction was used to detect the expression of the M1/M2 microglia polarization markers, HMGB1, and RAGE. Microglial activation and phenotypic transformation in the hippocampus were identified. mRFP-GFP-LC3 and Western blotting were used to detect autophagy flux in each treatment group. Finally, an LPS-induced BV2 cell model was developed to verify the involvement of the HMGB1-RAGE pathway, autophagy flux, and polarization. Ketamine improved LPS-induced depression-like behavior, inhibited the LPS-induced upregulation of HMGB1 and RAGE and the nuclear translocation of HMGB1. Moreover, ketamine reversed the blocked autophagy flux of microglia caused by LPS and regulated microglial autophagy flux through the HMGB1-RAGE pathway and microglial polarization. These results suggest that ketamine may reduce HMGB1 and RAGE accumulation in patients with depression, thereby providing a new therapeutic target for preventing and treating this disease.
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 81 (11) , 931-942
Ketamine Regulates the Autophagy Flux and Polarization of Microglia through the HMGB1-RAGE Axis and Exerts Antidepressant Effects in Mice
Depression is a leading cause of disability worldwide. Here, we explored the role of the HMGB1-RAGE pathway in lipopolysaccharide (LPS)-induced depression-like behavior and microglial autophagy flux, neuroinflammation, and polarization in a mouse model. Male C57BL/6 mice were infused with LPS in the abdominal cavity to induce a depression model. They then underwent testing to assess behavior and cognition. Real-time fluorescent quantitative polymerase chain reaction was used to detect the expression of the M1/M2 microglia polarization markers, HMGB1, and RAGE. Microglial activation and phenotypic transformation in the hippocampus were identified. mRFP-GFP-LC3 and Western blotting were used to detect autophagy flux in each treatment group. Finally, an LPS-induced BV2 cell model was developed to verify the involvement of the HMGB1-RAGE pathway, autophagy flux, and polarization. Ketamine improved LPS-induced depression-like behavior, inhibited the LPS-induced upregulation of HMGB1 and RAGE and the nuclear translocation of HMGB1. Moreover, ketamine reversed the blocked autophagy flux of microglia caused by LPS and regulated microglial autophagy flux through the HMGB1-RAGE pathway and microglial polarization. These results suggest that ketamine may reduce HMGB1 and RAGE accumulation in patients with depression, thereby providing a new therapeutic target for preventing and treating this disease.
- Open Access
- 22 November 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (12) , e32420
Identification of risk factors for postoperative delirium in elderly patients with hip fractures by a risk stratification index model: A retrospective study
Introduction: Postoperative delirium is one of the most common and dangerous psychiatric complications after hip surgery. The aim of this study was to investigate the incidence of postoperative delirium in elderly patients after hip fracture surgery and to identify risk factors for such, as part of developing a risk stratification index (RSI) system to predict a patient's risk of postoperative delirium.Methods: Elderly patients (aged 65 years or older) with hip fractures who had received surgical treatment in our hospital between March 2018 and December 2019 were retrospectively included. Clinical data were collected, and multivariate logistic regression analysis was performed to investigate the relevant risk factors of postoperative delirium. An RSI system was developed based on factors identified in the regression analysis.Results: Of 272 patients included, 52 (19.12%) experienced postoperative delirium. Drinking history (> 3/ week), the perioperative lactic acid level (Lac > 2 mmol/L), postoperative visual analog score (VAS) > 3, American Society of Anesthesiologists (ASA) physical status > II, application of the bispectral index, and preoperative diabetes were independent risk factors of postoperative delirium. When RSI ≥ 5, the rate of postoperative delirium significantly increased (p < .05).Conclusion: The RSI system developed here can safely guide postoperative outcomes of elderly patients with hip fractures, and RSI ≥ 5 may be able to predict the onset of postoperative delirium.
- 22 November 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (12) , e32420
Open AccessIdentification of risk factors for postoperative delirium in elderly patients with hip fractures by a risk stratification index model: A retrospective study
Introduction: Postoperative delirium is one of the most common and dangerous psychiatric complications after hip surgery. The aim of this study was to investigate the incidence of postoperative delirium in elderly patients after hip fracture surgery and to identify risk factors for such, as part of developing a risk stratification index (RSI) system to predict a patient's risk of postoperative delirium.Methods: Elderly patients (aged 65 years or older) with hip fractures who had received surgical treatment in our hospital between March 2018 and December 2019 were retrospectively included. Clinical data were collected, and multivariate logistic regression analysis was performed to investigate the relevant risk factors of postoperative delirium. An RSI system was developed based on factors identified in the regression analysis.Results: Of 272 patients included, 52 (19.12%) experienced postoperative delirium. Drinking history (> 3/ week), the perioperative lactic acid level (Lac > 2 mmol/L), postoperative visual analog score (VAS) > 3, American Society of Anesthesiologists (ASA) physical status > II, application of the bispectral index, and preoperative diabetes were independent risk factors of postoperative delirium. When RSI ≥ 5, the rate of postoperative delirium significantly increased (p < .05).Conclusion: The RSI system developed here can safely guide postoperative outcomes of elderly patients with hip fractures, and RSI ≥ 5 may be able to predict the onset of postoperative delirium.
- Open Access
- 15 November 2021
- Published by Springer Nature in Research Square
Intrathecal Analgesia Via a Percutaneous Port For the Management of Movement-Evoked Breakthrough Cancer Pain of Refractory Lower Extremity Cancer Pain: A Retrospective Review and Commentary
Background and Objectives: Intrathecal analgesia (ITA) is a trusty treatment option for refractory and intractable cancer pain. However, there is still no general consensus on the analgesic effect of movement-evoked breakthrough pain (MEBTP) in the ITA setting. This study examined the effect of patient-controlled intrathecal analgesia (PCIA) on analgesic efficacy, emphasizing movement evoked breakthrough pain (MEBTP) in patients with refractory lower extremity cancer pain. Methods: A retrospective chart review included all patients with refractory lower extremity cancer pain who received Intrathecal morphine infusion therapy via percutaneous port (IMITPP) at our hospital between January 2017 and December 2020. Data on the numerical pain rating scales (NRS) scores, opioid doses, and complications were collected from medical records prior to IMITPP and at a one-month postimplant visit.Results: A total of 16 patients were included in the study group. Mean SRPI (spontaneous resting pain intensity) decreased from 8.75 pre- IMITPP to 3.75 post- IMITPP, (P < 0.001); mean MEPI (movement-evoked breakthrough pain intensity) fell from 8.83 pre- IMITPP to 4.25 post- IMITPP (P < 0.001); mean daily morphine equivalent dosing decreased from 360 mg/d to 48mg/d (P< 0.001); mean daily morphine equivalent dosing for MEBTP decreased from 87 mg/d to 6 mg/d (P< 0.001). Both total and breakthrough dosing of conventional opioid medications significantly decreased following the initiation of ITT with PCIA. The mean perceived time to onset with conventional movement evoked breakthrough medications was 38 minutes, and the mean perceived time to onset with PCIA was 8 minutes (P < 0.001). Conclusions: IMITPP was associated with improved pain control in patients with refractory lower extremity cancer pain. Compared with conventional MEBTP medication, appropriate PCIA provided superior analgesia and a much faster onset of action.
- 15 November 2021
- Published by Springer Nature in Research Square
Open AccessIntrathecal Analgesia Via a Percutaneous Port For the Management of Movement-Evoked Breakthrough Cancer Pain of Refractory Lower Extremity Cancer Pain: A Retrospective Review and Commentary
Background and Objectives: Intrathecal analgesia (ITA) is a trusty treatment option for refractory and intractable cancer pain. However, there is still no general consensus on the analgesic effect of movement-evoked breakthrough pain (MEBTP) in the ITA setting. This study examined the effect of patient-controlled intrathecal analgesia (PCIA) on analgesic efficacy, emphasizing movement evoked breakthrough pain (MEBTP) in patients with refractory lower extremity cancer pain. Methods: A retrospective chart review included all patients with refractory lower extremity cancer pain who received Intrathecal morphine infusion therapy via percutaneous port (IMITPP) at our hospital between January 2017 and December 2020. Data on the numerical pain rating scales (NRS) scores, opioid doses, and complications were collected from medical records prior to IMITPP and at a one-month postimplant visit.Results: A total of 16 patients were included in the study group. Mean SRPI (spontaneous resting pain intensity) decreased from 8.75 pre- IMITPP to 3.75 post- IMITPP, (P < 0.001); mean MEPI (movement-evoked breakthrough pain intensity) fell from 8.83 pre- IMITPP to 4.25 post- IMITPP (P < 0.001); mean daily morphine equivalent dosing decreased from 360 mg/d to 48mg/d (P< 0.001); mean daily morphine equivalent dosing for MEBTP decreased from 87 mg/d to 6 mg/d (P< 0.001). Both total and breakthrough dosing of conventional opioid medications significantly decreased following the initiation of ITT with PCIA. The mean perceived time to onset with conventional movement evoked breakthrough medications was 38 minutes, and the mean perceived time to onset with PCIA was 8 minutes (P < 0.001). Conclusions: IMITPP was associated with improved pain control in patients with refractory lower extremity cancer pain. Compared with conventional MEBTP medication, appropriate PCIA provided superior analgesia and a much faster onset of action.